Market Overview

Toying With Tariffs: Trade War With Mexico Could Hurt Mattel, While China Spat Affects Hasbro

Share:
Toying With Tariffs: Trade War With Mexico Could Hurt Mattel, While China Spat Affects Hasbro

For toymakers Hasbro, Inc. (NASDAQ: HAS) and Mattel Inc., (NASDAQ: MAT), American saber-rattling on trade is no child’s play.

The impact of high tariffs on products coming from Mexico — a threat made last week by the Trump administration — and China, with which the administration is in a major trade dispute — could hit both companies’ margins. 

Mattel is most at risk in Mexico and Hasbro has the most exposure in China, UBS Global Research analyst Arpine Kocharyan said in a Wednesday note. 

Mattel And Mexico

For Mattel, two out of its 13 owned manufacturing plants are in Mexico, and about half of the company’s toys are made in owned manufacturing plants, the analyst said. (See his track record here.)

If tariffs go from 5 percent to 25 percent later in the year, as Trump threatened last week on Twitter, Mattel has indicated an operating profit exposure of between $5 million and $15 million, or anywhere from a penny to 3 cents in EPS, Kocharyan said.

The annualized impact would be closer to 6 cents or 7 cents, with about $250 million to $350 million of exposure to Mexico-sourced U.S. sales for Mattel, the analyst said. 

Hasbro And China

Hasbro, on the other hand, is mostly insulated from any Mexican tariff impact, according to UBS.

The amount of product sourced in the country is mostly just for local production, Kocharyan said — but the bad news is that Hasbro sources most of its toys from China.

As of right now, there's no direct impact from China tariffs, as toys are consumer goods and therefore have not been included on the list of tariff targets, the analyst said. 

If the trade war continues to escalate, it could have a big effect, Kocharyan said. About 69 percent of Hasbro’s global product is manufactured in China, with most of that coming to the United States, he said.

The company has reduced its exposure, the analyst said: more than 85 percent of its product originated in China as recently as 2012.

“While toy makers can over time reengineer product to take some of the cost out to keep price [points] optimal for the consumer, it could be challenging to readjust manufacturing immediately (or shift production geographically), in case tariffs were to be implemented." 

UBS has Neutral ratings on both stocks.

Kocharyan reminded investors that S&P MidCap400 constituent Bemis Company, Inc. (NYSE: BMS) will replace Mattel in the S&P 500, and Mattel will replace Bemis in S&P MidCap 400 prior to the market open June 7.

Price Action

Hasbro shares were trading flat at the $103 level at the time of publication Wednesday, while Mattel shares were up 1.81 percent at $10.98. 

Related Links:

Toy Companies Hasbro, Mattel, Not Back to Normal Yet

Optimism In Toyland: Wells Fargo Likes Mattel, Hasbro Moving Forward

Latest Ratings for HAS

DateFirmActionFromTo
Jul 2019MaintainsHold
May 2019MaintainsBuy
May 2019MaintainsMarket PerformMarket Perform

View More Analyst Ratings for HAS
View the Latest Analyst Ratings

Posted-In: Arpine KocharyanAnalyst Color Government News Regulations Reiteration Global Analyst Ratings Best of Benzinga

 

Related Articles (BMS + HAS)

View Comments and Join the Discussion!

Latest Ratings

StockFirmActionPT
MANMaintains96.0
INTCMaintains57.0
CHNGInitiates Coverage On19.0
BRMaintains150.0
SLBMaintains41.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com

InflaRx Shares Slammed As Skin Inflammation Drug Flunks Midstage Trial; ChemoCentryx Moves In Sympathy

Investors Show Optimism As Grassley Says He Doesn't Expect Mexican Tariffs To Take Effect